SPR as a New Technology in Clinical Research





The interactive transcript could not be loaded.


Rating is available when the video has been rented.
This feature is not available right now. Please try again later.
Published on May 7, 2014

Infliximab is a chimeric monoclonal antibody that targets tumor necrosis factor-alpha and is used to treat a variety of chronic autoimmune disorders such as rheumatoid arthritis, Crohn's disease and ulcerative colitis. Monitoring serum infliximab concentrations is important in guiding disease management, especially when a patient is not responding well to treatment. Infliximab concentrations can determine if loss of efficacy is due to inadequate dose or to the development of anti-infliximab antibodies.

Currently, 3 reference labs offer quantitative infliximab testing. However, the high cost of these tests limits frequency of use. Here, using the ProteOn XPR36, we describe development of a quantitative assay for infliximab in serum, and explore the practicality of using surface plasmon resonance in the clinical lab.


We Are Bio-Rad.

Our mission: To provide useful, high-quality products and services that advance scientific discovery and improve healthcare. At Bio-Rad, we are united behind this effort. These two objectives are the driving force behind every decision we make, from developing innovative ideas to building global solutions that help solve our customers' greatest challenges.

Connect with Bio-Rad Online:
Website: http://www.bio-rad.com/
LinkedIn: https://www.linkedin.com/company/1613...
Facebook: https://www.facebook.com/biorad/
Twitter: https://twitter.com/BioRadLifeSci
Instagram: @BioRadLabs
Snapchat: @BioRadLabs


When autoplay is enabled, a suggested video will automatically play next.

Up next

to add this to Watch Later

Add to

Loading playlists...